ロード中...
Erlotinib-Cisplatin Combination Inhibits Growth and Angiogenesis through c-MYC and HIF-1α in EGFR-Mutated Lung Cancer In Vitro and In Vivo
Combination treatment for non–small cell lung cancer (NSCLC) is becoming more popular due to the anticipation that it may be more effective than single drug treatment. In addition, there are efforts to genetically screen patients for specific mutations in light of attempting to administer specific a...
保存先:
| 出版年: | Neoplasia |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Neoplasia Press
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4351293/ https://ncbi.nlm.nih.gov/pubmed/25748238 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neo.2014.12.008 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|